About: Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients
Creator	Bosch-Barrera, Joaquim Brunet, Joan Buxó, Maria Encinar, José Martin-Castillo, Begoña Menendez, Javier
source	Medline; PMC
abstract	COVID-19, the illness caused by infection with the novel coronavirus SARS-CoV-2, is a rapidly spreading global pandemic in urgent need of effective treatments. Here we present a comprehensive examination of the host- and virus-targeted functions of the flavonolignan silibinin, a potential drug candidate against COVID-19/SARS-CoV-2. As a direct inhibitor of STAT3—a master checkpoint regulator of inflammatory cytokine signaling and immune response—silibinin might be expected to phenotypically integrate the mechanisms of action of IL-6-targeted monoclonal antibodies and pan-JAK1/2 inhibitors to limit the cytokine storm and T-cell lymphopenia in the clinical setting of severe COVID-19. As a computationally predicted, remdesivir-like inhibitor of RNA-dependent RNA polymerase (RdRp)—the central component of the replication/transcription machinery of SARS-CoV-2—silibinin is expected to reduce viral load and impede delayed interferon responses. The dual ability of silibinin to target both the host cytokine storm and the virus replication machinery provides a strong rationale for the clinical testing of silibinin against the COVID-19 global public health emergency. A randomized, open-label, phase II multicentric clinical trial (SIL-COVID19) will evaluate the therapeutic efficacy of silibinin in the prevention of acute respiratory distress syndrome in moderate-to-severe COVID-19-positive onco-hematological patients at the Catalan Institute of Oncology in Catalonia, Spain.
has issue date	2020-06-07(xsd:dateTime)
bibo:doi	10.3390/jcm9061770
bibo:pmid	32517353
has license	cc-by
sha1sum (hex)	c5d0f04df7115143b457ffd1334c93cc8cc8dd98
schema:url	https://doi.org/10.3390/jcm9061770
resource representing a document's title	Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients
has PubMed Central identifier	PMC7356916
has PubMed identifier	32517353
schema:publication	J Clin Med
resource representing a document's body	covid:c5d0f04df7115143b457ffd1334c93cc8cc8dd98#body_text
is schema:about of	named entity 'replication' named entity 'limit' named entity 'signaling' named entity 'direct' named entity 'therapeutic' named entity 'responses' named entity 'rapidly' named entity 'silibinin' named entity 'mechanisms' named entity 'pandemic' named entity 'cytokine storm' named entity 'inhibitor' named entity 'Replication' named entity 'SPAIN' named entity 'MODERATE-TO-SEVERE' named entity 'CENTRAL' named entity 'STRONG' named entity 'INFLAMMATORY CYTOKINE' named entity 'INTERFERON ' named entity 'impede' named entity 'polymerase' named entity 'clinical trial' named entity 'Catalan' named entity 'inhibitors' named entity 'viral load' named entity 'positive feedback' named entity 'acute respiratory distress syndrome' named entity '2020 SARS-CoV-2 pandemic' named entity 'homology model' named entity 'silibinin' named entity 'STAT3' named entity 'papain' named entity 'liver' named entity 'homology model' named entity 'ritonavir' named entity 'Flaviviridae' named entity 'RNA binding' named entity 'COVID-19' named entity 'inflammation' named entity 'IL-10' named entity 'FDA' named entity 'strong' named entity 'regulator' named entity 'comprehensive examination' named entity 'Catalonia' named entity 'Spain' named entity 'interferon' named entity 'virus' named entity 'mechanisms of action' named entity 'flavonolignan' named entity 'coronavirus' named entity 'SARS-CoV-2' named entity 'clinical testing' named entity 'COVID' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'silibinin' named entity 'inflammatory cytokine' named entity 'RdRp' named entity 'Cytokine Storm' named entity 'Virus Replication' named entity 'SARS-CoV-2' named entity 'tumor cells' named entity 'evidence-based' named entity 'SARS-CoV-2' named entity 'macrophages' named entity 'public health emergency of international concern' named entity 'IFN' named entity 'epithelial cells' named entity 'silibinin' named entity 'Food and Drug Administration' named entity 'HCV' named entity 'primary endpoint' named entity 'evolution' named entity 'life-threatening' named entity 'morbidity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software